• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ANGIOMED GMBH & CO. MEDIZINTECHNIK KG E-LUMINEXX VASCULAR STENT; VASULAR STENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ANGIOMED GMBH & CO. MEDIZINTECHNIK KG E-LUMINEXX VASCULAR STENT; VASULAR STENT Back to Search Results
Catalog Number UNK E-LUMINEXX VASCULAR STENT
Device Problem Obstruction of Flow (2423)
Patient Problem Occlusion (1984)
Event Date 07/28/2008
Event Type  Injury  
Manufacturer Narrative
As the lot number for the device was not provided, a manufacturing review could not be performed.The sample was not returned to the manufacturer for inspection/evaluation.Therefore, the investigation of the reported event is inconclusive.Based upon the available information, the definitive root cause for this event is unknown.The instructions for use (ifu) is adequate for the reported device/patient code(s) and provides general instructions for use, as well as warnings, precautions and potential complications associated with the device.Upon receipt of new or additional information, a follow-up report will be submitted as applicable.Journal article citation: lou, w.-s., gu, j.-p., he, x., chen, l., su, h.-b., chen, g.-p., wang, t.(2009).Endovascular treatment for iliac vein compression syndrome: a comparison between the presence and absence of secondary thrombosis.Korean journal of radiology, 10(2), 135.Doi: 10.3348/kjr.2009.10.2.135.
 
Event Description
It was reported in an article from korean journal of radiology titled " endovascular treatment for iliac vein compression syndrome: a comparison between the presence and absence of secondary thrombosis " that after stent placement in two iliac vein compression syndrome (ivcs) patients with recurrent dvt present (3 and 6 months after discharge follow-up evaluation showing the in-stent restenosis), blood flow was successfully restored in one case by percutaneous transluminal angioplasty (pta) and not in the other due to the inability to pass the catheter and wire beyond the obstruction.The status of the patients was not provided.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
E-LUMINEXX VASCULAR STENT
Type of Device
VASULAR STENT
Manufacturer (Section D)
ANGIOMED GMBH & CO. MEDIZINTECHNIK KG
wachhausstrasse 6
karlsruhe 76227
GM  76227
Manufacturer (Section G)
ANGIOMED GMBH & CO. MEDIZINTECHNIK KG
wachhausstrasse 6
karlsruhe 76227
GM   76227
Manufacturer Contact
judith ludwig
1415 w. 3rd street
tempe, AZ 85281
4803032689
MDR Report Key9516533
MDR Text Key172606978
Report Number2020394-2019-05845
Device Sequence Number1
Product Code NIO
Combination Product (y/n)N
Reporter Country CodeCH
PMA/PMN Number
P080007
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,l
Reporter Occupation Non-Healthcare Professional
Type of Report Initial
Report Date 12/24/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue NumberUNK E-LUMINEXX VASCULAR STENT
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 12/11/2019
Initial Date FDA Received12/24/2019
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
ASPIRIN 75-300MG OD FOR 6-12 MONTHS; LOW MOLECULAR HEPARIN 4100U FOR 3-5 DAYS; UROKINASE DAILY 250,000-1,000,000U; WARFARIN 1.25 - 5 MG OD FOR 1-6 MONTHS
Patient Outcome(s) Required Intervention;
-
-